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Abstract 
 
The mechanisms of lung microvascular complications and pulmonary 
hypertension known to be associated with idiopathic pulmonary fibrosis (IPF), a 
debilitating lung disease, are not known. The bioactive lipid signal mediator, 
phosphatidic acid (PA), generated by phospholipase D (PLD), is emerging as a key 
player in vascular endothelial dysfunctions. Therefore, we investigated whether 
bleomycin, the widely used experimental IPF inducer, would be capable of activating 
PLD and generating PA in our established bovine lung microvascular EC (BLMVEC) 
model. Our results revealed that bleomycin induced the activation of PLD and generation 
of PA in a dose-dependent (0-100 µg) and time-dependent (2-12 h) fashion that were 
significantly attenuated by the PLD-specific inhibitor, 5-fluoro-2-indolyl des-
chlorohalopemide (FIPI). PLD activation and PA generation induced by bleomycin (5 
µg) were significantly attenuated by the thiol protectant (N-acetylcysteine), antioxidants, 
and iron chelators, suggesting the role of reactive oxygen species (ROS), lipid 
peroxidation, and iron therein. Furthermore, our study demonstrated the formation of 
ROS and loss of glutathione (GSH) in cells following bleomycin treatment, confirming 
oxidative stress as a key player in the bleomycin-induced PLD activation and PA 
generation in ECs. More noticeably, PLD activation and PA generation were observed to 
occur upstream of cytotoxic response (cell morphology alterations or lactate 
dehydrogenase release) in BLMVECs, which was protected by FIPI. Overall, this study 
revealed novel information that bleomycin induced the redox-sensitive activation of PLD 
leading to the generation of PA, capable of inducing lung EC cytotoxicity, thus 
suggesting possible mechanism(s) of microvascular disorders encountered in IPF.  
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Introduction 
  Cellular membranes, including the plasma membrane and membranes of 
organelles, consist of phospholipids, proteins, and carbohydrate moieties. The membrane 
phospholipids are critical for cell structure and function and the cellular homeostasis and 
survival. Cellular signaling is one of the crucial cell functions required for homeostasis. 
Enzymes belonging to the family of membrane phospholipid hydrolases called 
“phospholipases” are both the house-keeping enzymes as well as the cellular signal 
transduction-mediating enzymes. Phospholipases A
1 
(PLA
1
), A
2 
(PLA
2
), C (PLC), and D 
(PLD) act on the membrane phospholipids at specific sites to generate bioactive lipid 
signal mediators which induce cellular signals at targets leading to cellular functional 
responses (Steinhour et al., 2007). Phospholipase D (PLD) is one such membrane 
phospholipid hydrolase which generates a potent cellular bioactive lipid signal mediator, 
phosphatidic acid (PA), which, in turn is further metabolized into potent bioactive lipid 
signal mediators such as diacylglycerol (DAG) and lysophosphatidic acid (LPA) 
(Parinandi et al., 1999; Cummings et al., 2002). PLD has been shown to be involved in 
several pathophysiological conditions such as cardiovascular diseases and cancer (Tappia 
et al., 2006; Su et al., 2009). Thus, the PLD-generated bioactive lipid mediators (PA, 
DAG, and LPA) regulate the cellular cytoskeleton, especially the actin cytoskeleton, 
which leads to the regulation and/or alteration of the cell shape and movement.  
PLD activation in mammalian cells is under the control of several regulators 
including hormones, growth factors, G protein-coupled receptors, and other bioactive 
signal mediators through the regulation of protein kinases such as protein kinase C, 
tyrosine kinase, and mitogen-activated protein kinases (Steinhour et al., 2007). Oxidative 
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stress and oxidant exposure (reactive oxygen species, ROS) are known to activate PLD in 
mammalian cells (Varadharaj et al., 2006). Vascular endothelial cells (ECs), the inner 
monolayer lining of blood vessels which form the barrier, are susceptible to oxidative 
stress that leads to vascular endothelial cell disruption and vascular leak.  Oxidative 
stress-induced activation of PLD and associated lipid-signaling enzymes are emerging as 
responsible players for EC dysfunction leading to pathophysiological conditions in lung 
vasculature during oxidant exposure such as infection, pulmonary hypertension, lung 
fibrosis, and hyperoxic lung damage. Oxidative stress also leads to the redox perturbation 
in the cells such as alterations in the soluble thiols (glutathione, GSH) and protein thiols 
(Parinandi et al., 1999). However, the thiol redox-modulation of oxidative stress-
mediated activation of PLD in lung ECs is not completely understood. Therefore, here, it 
is hypothesized that oxidative stress induced by oxidants induces an imbalance in the 
thiol redox of the lung vascular ECs so that the redox-sensitive PLD is activated, 
resulting in the generation of the bioactive lipid mediator, PA, that ultimately signals the 
vascular EC barrier dysfunction.  
Idiopathic pulmonary fibrosis (IPF) is a degenerative, chronic, and progressive 
fibrosing lung disorder of the tissue that lines and separates the alveoli with unknown 
etiology (Kinnula et al., 2005).  The prevalence of IPF in the US is estimated in the range 
of 35,000 to 55,000 cases as recorded in 2005 (Zisman et al., 2005). Extended exposure 
to environmental and occupational agents including metal dust, wood dust, and stone dust 
have been associated with the tissue damage that leads to IPF among the idiopathic lung 
diseases (Taskar and Coultas, 2008; Wilson and Wynn, 2009). IPF is a progressive 
interstitial lung disorder where the tissue that lines and separates the alveoli becomes 
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scarred due to lung damage.  This scarring causes the tissue to become inelastic and hard.  
The buildup of scar tissue causes difficulties in breathing and results in respiratory 
failure.  Interstitial lung diseases (ILD) including the sarcoidosis, IPF, and pulmonary 
Langerhans cell histiocytosis have been shown to be associated with pulmonary 
hypertension (PH) (Ryu et al., 2007; Cordier, 2008). Lung parenchymal and vascular 
remodeling indicates the high prevalence (30-40%) of PH among the ILD patients (Behr 
and Ryu, 2008). Although both the lung epithelium and endothelium have been shown to 
be the critical cellular players in IPF, microvascular injury has been shown as an initial 
event in lungs during IPF (Calabrese et al., 2005). In addition, microvascular injury has 
been emphasized as an important event in the evolution of IPF (Magro et al., 2003). 
Therefore, the lung microvasculature, specifically the lung microvascular endothelium, is 
apparently a target in the lung fibrotic events.  Bleomycin is widely used as an 
experimental lung fibrosis inducer (Tager et al., 2008).  Since vascular endothelial 
alterations are encountered in lung fibrosis, both experimental and disease settings, we 
rationalized that bleomycin is a suitable model lung fibrosis inducer to study the vascular 
endothelial alterations through PLD signaling in cultured lung ECs.  This will provide an 
understanding of PLD signaling-mediated lung EC damage associated with IPF.  
 Several cellular signaling mechanisms involving caveolae, caveolins, protein 
kinases, focal adhesion kinase, protein kinase B, and mitogen-activated protein kinases 
(MAPKs) have been shown to operate in IPF (Gosens et al., 2008; Garneau-Tsodikova 
and Thannickal, 2008; Chopra et al., 2008). Studies with experimental models have 
revealed the roles of oxidative stress and antioxidant imbalance in the initiation and 
progression of IPF.  Accordingly, redox modulatory therapy has been proposed for the 
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treatment of the disease (Kinnula et al., 2005; Kinnula and Myllarniemi, 2008). As the 
lung microvasculature and vascular endothelium are critical regions in IPF, oxidative 
stress and redox alterations appear to drive the initiation and progression of IPF, and 
oxidants are known to activate the lung vascular endothelial PLD leading to the 
generation of bioactive lipid mediators, it is compelling to rationalize that oxidant-
mediated lung microvascular endothelial PLD signaling is likely to play a crucial role in 
the initiation and propagation of IPF. To date, no reports have been made on the 
activation of PLD by the experimental lung fibrosis inducer, bleomycin, in lung cells 
including the vascular endothelium. Therefore, here, we have hypothesized that 
bleomycin induces oxidant-mediated and redox-dependent PLD activation upstream that 
leads to the cytotoxicity downstream through the PLD-generated bioactive lipid mediator, 
PA in the lung microvascular endothelial cells (ECs) in culture. To test this hypothesis, 
we used the well-established bovine lung microvascular ECs (BLMVECs) and exposed 
them to the experimental lung fibrosis inducer, bleomycin, to establish the thiol-redox 
regulation of PLD activation in lung ECs and define the connection between the upstream 
PLD activation and downstream cytotoxicity that could be responsible for the oxidant-
mediated lung vascular dysfunction similar to that encountered in IPF conditions. For the 
first time, the results of the current study revealed that the experimental lung fibrosis 
inducer, bleomycin, induced the upstream activation of PLD and generated the bioactive 
lipid signal mediator, PA, in oxidant-mediated and redox-dependent mechanism that 
caused cytotoxicity in the lung microvascular ECs in culture, suggesting the possible role 
of PLD in IPF. 
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Materials and Methods 
 Materials  
BLMVECs (passage 4) were purchased from VEC Technologies (NY, USA). Phosphate-
buffered saline (PBS) was obtained from Biofluids Inc. (Rockville, MD). Minimal 
essential medium (MEM), nonessential amino acids, trypsin, fetal bovine serum (FBS), 
penicillin/streptomycin, DMEM phosphate-free modified medium, tissue culture 
reagents, and analytical reagents of highest purity were all purchased from Sigma 
Chemical Co. (St. Louis, MO). Phosphatidylbutanol (PBt) was obtained from Avanti 
Polar Lipids (Alabaster, AL). [32P] Orthophosphate (carrier-free) was obtained from New 
England Nuclear (Wilmington, DE). Bleomycin was obtained from Teva Parenteral 
Medicines (Irvine, CA). Desferal was obtained from Calbiochem (San Diego, CA). 
Polyclonal antibody to 4-Hydroxynonenal (anti-HNE) was obtained from Enzo Life 
Sciences (Farmingdale, NY). Endothelial cell growth factor was obtained from Upstate 
Biotechnology (Lake Place, NY). 5-Fluoro-2-indolyl des-clorohalopemide hydrochloride 
hydrate (FIPI) was obtained from Dr. Andrew J. Morris of University of Kentucky. GSH-
Glo Glutathione Assay kit was obtained from Promega Corporation (Madison, WI) 
Cell culture    
BLMVECs were grown to confluence in MEM supplemented with 10% (v/v) 
fetal bovine serum, 100 units/ml penicillin and streptomycin, 5 μg/ml endothelial cell 
growth factor and 1% (v/v) nonessential amino acids at 37 oC under a humidified 95% 
air-5% CO2 atmosphere as described earlier (Steinhour et al., 2007). BLMVECs, from 
passages 7 to 15, were used in the experiments.  ECs cultured in 35-mm or 60-mm sterile 
dishes or T-75 cm sterile flasks to ~95% confluence under a humidified 95% air-5% CO2 
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atmosphere were used for treatments with bleomycin and desired pharmacological 
agents. MEM containing bleomycin and other pharmacological agents were carefully 
adjusted to pH 7.4 for cellular treatments. 
Phospholipase D activation in intact ECs 
ECs in 35-mm dishes (5 x 105 cells/dish) were labeled with [32P]orthophosphate 
(5 μCi/ml) in DMEM phosphate-free medium containing 2% (v/v) fetal bovine serum for 
12-14 h (Varadharaj et al., 2006). Cells were washed with MEM and incubated at 37 oC 
in 1 ml of MEM containing 0.05% (v/v) 1-butanol in absence and presence of desired 
concentrations of bleomycin for different lengths of time under a humidified 95% air-5% 
CO2 atmosphere. In some experiments, wherever required, ECs were pretreated for 2 h or 
12 h with selected pharmacological inhibitors prior to exposure to bleomycin or co-
treated with bleomycin and pharmacological inhibitors for the desired lengths of 
incubation time. The incubations were terminated by addition of 1 mL methanol:HCl 
(100:1, by vol.). Lipids were extracted essentially according to the method of Bligh and 
Dyer procedure as described previously (Steinhour et al., 2007). [32P]-Labeled 
phosphatidylbutanol (PBt) formed as a result of PLD activation and 
transphosphatidylation reaction, as an index of PLD activity in intact cells, was separated 
by thin-layer chromatography (TLC) (Varadharaj et al., 2006; Steinhour et al, 2007). 
Radioactivity associated with the [32P]-PBt was quantified by liquid scintillation counting 
and data were expressed as DPM normalized to 106 counts in the total cellular lipid 
extract or as % of control (vehicle-treated cells). 
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Reactive oxygen species (ROS) measurement by DCFDA fluorescence 
Formation of ROS in BLMVECs in 35-mm dishes (5x105 cells/dish) was 
determined by DCFDA fluorescence in cells preloaded with 10 µM DCFDA for 30 min 
in complete MEM at 37° C in a 95% air-5% CO2 environment prior to exposure to 
bleomycin for 1 h. At the end of exposure to bleomycin, the dishes containing the cells 
were either photographed using Olympus 1x50 fluorescent microscope with excitation 
and emission set at 490 nm and 530 nm respectively, or the cells were detached with a 
Teflon cell scraper. The medium which contained the cells was transferred to 1.5 mL 
microcentrifuge tubes and centrifuged at 8000 x g for 10 min at 4° C. The supernatant 
was aspirated and the cell pellet was washed twice with ice-cold phosphate-buffered 
saline (PBS). To prepare cell lysates, pellets were sonicated on ice with a probe sonicator 
at a setting of 2 for 15 s in 500 µL of ice-cold PBS. Fluorescence of oxidized DCFDA in 
cell lysates, an index of formation of ROS, was measured on a Bio-Tex ELx808 
fluorescent plate reader set at 490 nm and 530 nm respectively, using appropriate blanks. 
The extent of ROS formation was expressed as the arbitrary fluorescence units.  
(Hagele et al., 2007) 
GSH determination 
Intracellular soluble thiol levels were determined using the GSH-Glo Glutathione 
Assay.  BLMVECs grown up to 90% confluence in 96 well plates were treated with 
MEM containing desired concentrations of bleomycin for 12 h under a humidified 95% 
air-5% CO2 atmosphere. Following incubation, intracellular GSH levels were determined 
according to the manufacturer’s recommendations (Madison, WI). 
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Immunofluorescence microscopy 
BLMVECs cultured on sterile coverslips (Harvard Apparatus, 22 mm2) in 35-mm 
sterile dishes at a density of 104 cells/dish were treated with MEM alone and MEM 
containing bleomycin for 12 h under a humidified atmosphere of 95% air-5% CO2 at 37 
oC. At the end of the incubation period, cells attached to coverslips were washed with 1x 
PBS and fixed with 3.7% of para-formaldehyde for 10 min, permeabilized with 0.25% 
Triton X-100 in TBST containing 0.01% Tween-20 for 5 min, and blocked for 30 min 
with 1% BSA in 0.01% TBST and incubated for 12 h at room temperature with rabbit 
primary anti-4-HNE at a dilution of 1:200 for the visualization of 4-HNE formation. 
Following treatment of cells with the chosen primary antibodies, they were incubated 
with secondary anti-rabbit AlexaFluor 488-conjugated antibodies (1:100 dilution), for 1 h 
at room temperature. The coverslips with cells were then mounted on a glass slide with 
the antifade mounting medium, Fluoromount-G, viewed with Ziess Confocal microscope 
at a magnification of 60 X, and pictures were captured digitally.  
Morphology assay of cytotoxicity 
 Morphological changes in BLMVECs grown in 35-mm dishes up to 70% 
confluence, following their exposure to bleomycin (5 µg, 10 µg, and 100 µg) for specific 
times, were examined as an index of cytotoxicity. Images of cell morphology were 
digitally captured with the Olympus 1x50 at 20x magnification.  
Lactate dehydrogenase release (LDH) assay of cytotoxicity 
            Cytotoxicity in BLMVECs was determined by assaying the release of LDH from 
cells according to our previously published method (Mazerik et al. 2007).  BLMVECs 
grown up to 90% confluence in 35-mm dishes were treated with MEM containing desired 
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concentrations of bleomycin for different lengths of time under a humidified 95% air-5% 
CO2 atmosphere. In some experiments, wherever required, ECs were pretreated for 12 h 
with selected pharmacological inhibitors prior to exposure to bleomycin or co-treated 
with bleomyin and pharmacological inhibitors for 12 h. At the end of treatment, the 
medium was collected and LDH released into the medium was determined 
spectrophotometrically according to the manufacturer’s recommendations (Sigma 
Chemical Co., St. Louis, MO). The experiments were terminated with the addition of 1 N 
HCl. 
Protein determination 
Protein was determined by BCA protein assay (Pierce). 
Statistical analysis   
     All experiments were done in triplicate. Data were expressed as mean ± standard 
deviation (SD). Statistical analysis was carried out by ANOVA using SigmaStat (Jandel). 
The level of statistical significance was taken as P < 0.05.   
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Results 
Bleomycin induces PLD activation in a dose- and time-dependent fashion in ECs 
Bleomycin, in a dose-dependent manner (0-100 µg), at 4 and 12 h of incubation, 
induced significant activation of PLD in BLMVECs as compared with the vehicle-treated 
control cells (2-, 2-, and 3-fold for 4 h and 5-, 6-, and 12-fold for 12 h at 5, 10, and 100 
µg, respectively) (Fig. 1A). Incubation of ECs with bleomycin (5 µg) for 4, 8, 12, and 24 
h induced significant increases (2-, 3-, 4-, and 3-fold) in the activation of PLD as 
compared with that in the cells exposed to the MEM alone (Fig. 1B).  
 
Thiol-protectants attenuate bleomycin-induced PLD activation in ECs 
 
 Altered thiol redox has been shown to activate PLD in ECs. Therefore, to 
establish the role of thiols in bleomycin-induced PLD activation in ECs, here, the effects 
of well-established thiol protective agents (NAC and DTT) were investigated on PLD 
activation induced by bleomycin.  Cells were pretreated for 2 h with MEM alone or 
MEM containing the chosen thiol-protectant (0.5, 1 and 5 mM) and then co-treated for 12 
h with bleomycin (5 µg) and the chosen thiol-protectant.  NAC, a widely used thiol 
protectant and antioxidant, caused effective and significant attenuation of bleomycin-
induced PLD activation in ECs (22, 70, and 97% of inhibition for concentrations of 0.5, 
1, and 5 mM respectively) (Fig. 2A).  DTT, a sulfhydryl protective agent, also offered 
effective and significant attenuation of bleomycin-induced PLD activation in ECs (43, 
67, and 65% of inhibition for concentrations of 0.5, 1, and 5 mM respectively) (Fig. 2B).  
These results revealed that thiol-protectants effectively attenuated bleomycin-induced 
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PLD activation in ECs, further suggesting the involvement of cellular thiol status in the 
bleomycin-induced activation of PLD in ECs. 
 
 Heavy metal chelators attenuate bleomycin-induced PLD activation in ECs. 
 
Oxidative stress and ROS production has been shown to activate PLD in ECs. 
Heavy metals, particularly Fe2+, have been involved in the generation of ROS especially 
through fenton-type reactions. Bleomycin complexes with iron to become an active drug. 
Therefore, to establish the role of oxidative stress in bleomycin-induced PLD activation 
in ECs, here, the effects of well-established heavy metal chelators (EDTA, Desferal, and 
DMSA) were investigated on PLD activation induced by bleomycin.  Cells were 
pretreated for 2 h with MEM alone or MEM containing the chosen heavy metal chelator 
(2 mM for EDTA and Desferal, and 0.5, 1, 5 mM for DMSA) and then co-treated for 12 h 
with bleomycin (5 µg) and the chosen metal chelator.  EDTA and Desferal, widely used 
Fe2+ chelators, caused effective and significant attenuation of bleomycin-induced PLD 
activation in ECs (32 and 27% of inhibition respectively) (Fig. 3A and 3B).  DMSA, a 
heavy metal chelator and a thiol-redox stabilizer, also offered effective and significant 
attenuation of bleomycin-induced PLD activation in ECs (39, 64, and 64% of inhibition 
for concentrations of 0.5, 1, and 5 mM respectively) (Fig. 3C).  These results revealed 
that heavy metal chelators, especially Fe2+–specific chelators, effectively attenuated 
bleomycin-induced PLD activation in ECs, further suggesting the involvement of ROS 
production in the bleomycin-induced activation of PLD in ECs. 
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Antioxidants attenuate bleomycin-induced PLD activation in ECs. 
 
Oxidative stress, ROS production, and altered thiol redox has been shown to 
activate PLD in ECs. Moreover, bleomycin is established as an oxidant drug. We also 
found, previously in this study, that heavy metal chelators and thiol protectants 
effectively and significantly attenuated bleomycin-induced PLD activation in ECs. 
Therefore, in order to establish the role of oxidative stress in bleomycin-induced PLD 
activation in ECs, here, the effects of widely accepted antioxidants (PDTC, Propyl 
Gallate, Vitamin C, and MnTBAP) were investigated on PLD activation induced by 
bleomycin.  Cells were pretreated for 2 h with MEM alone or MEM containing the 
chosen antioxidant (0.5, 1, and 5 mM for PDTC, 500 µM for Propyl Gallate and Vitamin 
C, and 20 µM for MnTBAP) and then co-treated for 12 h with bleomycin (5 µg) and the 
chosen antioxidant.  PDTC caused effective and significant attenuation of bleomycin-
induced PLD activation in ECs (25, 49, and 72% of inhibition at 0.5, 1, and 5 mM 
respectively) (Fig. 4A).  Propyl Gallate, a phenolic antioxidant, and Vitamin C also 
offered effective and significant attenuation of bleomycin-induced PLD activation in ECs 
(49, and 46% respectively) (Fig. 4B and 4C).  MnTBAP, a superoxide scavenger, also 
offered effective and significant attenuation of bleomycin-induced PLD activation in ECs 
(21%) (Fig. 4D).  These results revealed that antioxidants effectively attenuated 
bleomycin-induced PLD activation in ECs, further suggesting the involvement of ROS in 
the bleomycin-induced activation of PLD in ECs. 
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 Lipid peroxidation inhibitors attenuate bleomycin-induced PLD activation in ECs. 
Oxidative stress and ROS production has been shown to induce lipid peroxidation 
in ECs. Therefore, in order to establish the role of lipid peroxidation in bleomycin-
induced PLD activation in ECs, here, the effects of lipid peroxidation antioxidants 
(NDGA and Trolox) were investigated on PLD activation induced by bleomycin.  Cells 
were pretreated for 2 h with MEM alone or MEM containing the chosen lipid 
peroxidation antioxidant (10, 20, and 50 µM for NDGA, and 100, 200, and 500 µM for 
Trolox) and then co-treated for 12 h with bleomycin (5 µg) and the chosen lipid 
peroxidation antioxidant. NDGA, a plant derived polyphenol, caused effective and 
significant attenuation of bleomycin-induced PLD activation in ECs (45, 72 and 67% of 
inhibition for 10, 20, and 50 µM NDGA, respectively) (Fig. 5A).  Trolox, a water soluble 
form of vitamin E, also offered effective and significant attenuation of bleomycin-
induced PLD activation in ECs (61, 69, and 71% of inhibition for concentrations of 100, 
200, and 500 µM Trolox, respectively) (Fig. 5B). These results revealed that lipid 
peroxidation antioxidants effectively attenuated bleomycin-induced PLD activation in 
ECs, further suggesting the involvement of lipid peroxidation in the bleomycin-induced 
activation of PLD in ECs. 
 
Bleomycin induces ROS generation in ECs.  
 
Bleomycin’s activity as a drug has been attributed to its ROS-forming nature. 
Earlier in the study we showed that bleomycin-induced PLD activation was attenueated 
by antioxidants, thus it was hypothesized that bleomycin would induce ROS formation in 
ECs.  DCFDA is a lipid-soluble probe that becomes fluorescent when oxidized by 
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multiple forms of ROS.  DCFDA fluorescence was measured as an index of ROS 
generation in ECs.  Bleomycin, in a dose-dependent manner (0-100 µg), at 1 h of 
incubation, induced significant ROS formation in BLMVECs as compared with the 
vehicle-treated control cells as seen by the relative fluorescence. Bleomycin, at 0.5 h of 
incubation, effectively induced ROS formation in BLMVECs as compared with the 
vehicle-treated control cells (1.5-, 1.8-, and 2-fold at 5, 10, and 100 µg, respectively). 
 
Bleomycin causes GSH depletion in ECs. 
 
Earlier in the study, we showed that thiol-protectants attenuated bleomycin-
induced PLD activation in ECs.  Therefore, we hypothesized that bleomycin depletes 
intracellular glutathione (GSH). To test this postulate, intracellular soluble thiols, GSH 
were measured.  Bleomycin in a dose-dependent manner induced significant GSH 
depletion in BLMVECs after a 12 h incubation as compared with the vehicle-treated 
control cells (60, 57, and 45% of the control for the 5, 10, and 100 µg, respectively).  
 
Bleomycin induces lipid peroxidation in ECs. 
 
Earlier in the study, we showed that bleomycin causes the production of ROS in 
ECs. ROS is known to cause lipid peroxidation of polyunsaturated fatty acids and 
produce highly reactive carbonyls such as 4-HNE. To observe if bleomycin induced lipid 
peroxidation in ECs, cells were treated with bleomycin for 12 h, fixed, and stained with 
anti-4-HNE antibodies. Using confocal microscopy, we showed that bleomycin induced 
the formation of 4HNE (as an index of lipid peroxidation) in a dose-dependant manner.  
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PLD inhibitor, FIPI, protects against bleomycin-induced PLD activation in ECs. 
 
We speculated that the cytotoxic effects of bleomycin were a result of the PLD–
generated PA. To test this premise, we wanted to inhibit PLD activity using a novel PLD 
inhibitor, FIPI. To validate the PLD inhibitor, FIPI (250, 500, and 1000 nM) was added 
to ECs for 12 h while they were being labeled with [32P]-orthophospate. The ECs were 
then co-treated with FIPI and bleomycin (5 µg) for 12 h. The results revealed that FIPI 
significantly attenuated bleomycin-induced PLD activation (25, 42, and 68 % at 250, 500, 
and 1000 nM respectively). FIPI was also found to inhibit the basal normal PLD activity 
(27, 47, and 62% at 250, 500, and 1000 nM respectively).  
 
Bleomycin induces morphological alterations in ECs. 
 
Since PLD is a bioactive lipid–signaling enzyme that plays an important role in 
EC function, we investigated the effects of bleomycin on the cell morphology as an index 
of disruption of cellular structure and cytotoxicity.  Cells were treated with bleomycin (5, 
10, and 100 µg) for 4, 8, 12, and 24 h before morphological images were taken digitally. 
Bleomycin in a time- and dose-dependant manner causes morphological alteration in 
ECs.  The results indicate that even with 5 µg of bleomycin, the morphological 
alterations begin before 4 h and the barrier is completely destroyed by 12 h.  
 
PLD inhibitor protects against bleomycin-induced morphological alterations in ECs. 
 
To investigate whether PLD activation has a role in the bleomycin-induced 
morphological alterations, we inhibited the PLD activity using FIPI and measured the 
bleomycin-induced morphological alterations.  Cells were pretreated with FIPI (1 µM) 
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for 12 h, and co-treated with bleomycin (5 µg) for 4, 8, 12 and 24 h before morphological 
images were taken digitally. FIPI was found to significantly attenuate bleomycin-induced 
morphological alterations at all time-points, implicating PLD activation in the bleomycin-
induced morphological alterations.  
 
Bleomycin induces cytotoxicity in ECs. 
 
As the PLD–generated PA was associated with cytotoxicity, another measure of 
cytotoxicity, the release of LDH was also measured. Bleomycin was found to increase the 
release of LDH in a dose- and time-dependant fashion. Bleomycin (5, 10, and 100 µg) 
caused LDH release of 20, 21, and 103% respectively at 8 h, 234, 250, and 266% 
respectively at 12 h, and 220, 244, and 302 % respectively at 24 h. These results indicate 
that bleomycin induces significant LDH release in ECs by 12 h.   
 
PLD inhibitor, FIPI, protects against bleomycin-induced cytotoxicity in ECs.  
 
Because the PA generated from PC through PLD has been implicated in many 
physiological disorders, we investigated if that the cytotoxic effects of bleomycin were 
caused by the PLD–generated PA. To measure the cytotoxic effects of the PLD generated 
PA, we assayed the bleomycin-induced LDH release in the ECs after inhibiting the PLD 
using FIPI. ECs were pretreated with FIPI (250, 500, and 1000 nM) for 12 h, before 
being exposed to bleomycin (5 µg) for 12 h. FIPI (250, 500, and 1000 nM) inhibited 
PLD-induced LDH release (23, 36, and 45%) implicating the role of PLD–generated PA 
in the bleomycin-induced cytotoxicity in ECs.  
 
 22 
Discussion: 
 
The results of the current study revealed that bleomycin at pharmacological doses 
(µU) induced the activation of PLD, which was attenuated by antioxidants, thiol-
protectants, and iron chelators, suggesting the upstream roles of oxidants and altered 
redox signaling in the activation of PLD in BLMVECs. This was further confirmed by 
the enhanced generation or ROS and decrease in thiol levels upon treatment of 
BLMVECs with bleomycin. FIPI, a PLD-specific inhibitor, caused complete inhibition of 
the bleomycin-induced activation of PLD and also offered protection against the 
cytotoxic effects of bleomycin in BLMVECs. Taken together, these results demonstrated 
the role of PLD-generated PA in the bleomycin-induced lung microvascular EC damage.  
Phospholipases are enzymes which specifically hydrolyze the membrane 
phospholipids and generate bioactive lipid second messengers, which may play a vital 
role in cell signaling (Devecha and Irvine, 1995). Phospholipase D (PLD) is one such 
lipid–signaling enzyme ubiquitously present in all mammalian cells that preferentially 
hydrolyzes phosphatidylcholine (PC) thus generating phosphatidic acid (PA) and choline 
(Exton, 1999). PA is further metabolized to either 1,2-diacylglycerol (DAG) by 
phosphatidate phosphohydrolase or lysophosphatidic acid (LPA) by phospholipase A1/A2 
(Natarajan, 1995; Brindley and Waggoner, 1996). Agonist-mediated activation of PLD 
plays a pivotal role in signal transduction in mammalian cells (Exton, 1997; Singer et al., 
1996). Several functions, including the promotion of mitogenesis in fibroblasts, 
stimulation of oxidative stress in neutrophils, increase of intracellular calcium, activation 
of protein kinases and phospholipases have been attributed to the signaling actions of PA 
and LPA (Exton, 1999). Two major forms of PLD, hPLD1 and hPLD2, have been cloned 
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in mammalian cells (Hammond et al., 1995; Colley et al., 1997; Lopez et al., 1998). Even 
though the two isoforms of PLD catalyze hydrolysis of PC to PA, they are selectively 
activated by various cofactors such as Arf, Rho, Cdc42, and detergents (Liscovitch and 
Chalifa-Caspi, 1996; Houle and Bourgoin, 1999). Phosphatidylinositol 4,5-bisphosphate 
(PIP2), a lipid mediator, activates both hPLD1 and hPLD2 in cell-free preparations. The 
results of the current work showed that bleomycin activated PLD in the BLMVECs 
generating the lipid signal mediator, PA.  This could be possible through the actions of 
both PLD1 and PLD2 isoforms as the presence of both the isoforms in ECs has been 
detected (Parinandi et al., 2001). However, the relative activity of these isoforms in the 
bleomycin-induced formation of PA is yet to be determined. 
Earlier studies have shown that reactive oxygen species (ROS) such as hydrogen 
peroxide, fatty acid hydroperoxide, 4-hydroxynonenal, and oxidized-LDL stimulated 
PLD in vascular ECs, smooth muscle cells, and fibroblasts (Natarajan and Garcia, 1993a; 
Natarajan et al., 1998; Natarajan et al., 1993b; Natarajan et al., 1993c; Kiss and 
Anderson, 1994; Min et al., 1998). The ROS-mediated PLD activation is attenuated by 
tyrosine kinase inhibitors and pretreatment of ECs with protein tyrosine phosphatase 
inhibitors such as vanadate, phenylarsine oxide, or diamide increases ROS-induced PLD 
activation several-fold, suggesting a role for protein tyrosine phosphorylation in PLD 
activation (Natarajan et al., 1996a and 1996b; Natarajan et al. 1998). In addition to 
tyrosine kinase inhibitors, PLD activation by oxidants was also attenuated by 
antioxidants, indicating redox regulation of PLD (Parinandi et al., 1999). Recently, we 
reported that mercury–activated PLD in the vascular ECs through thiol-redox alteration 
and generation of ROS (Hagele et al., 2007). Antioxidants including the thiol protectants 
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have been shown to attenuate the pro-oxidant-induced activation of PLD in lung 
microvascular ECs (Steinhour et al., 2008) suggesting the role of ROS and thiol-redox in 
the enzyme activation. Along these lines, the results of the current study also revealed 
that the bleomycin-induced PLD activation was regulated by the ROS, thiol-redox 
perturbation, and lipid peroxidation in BLMVECs. The results of the current study also 
suggested oxidant-induced and thiol-regulated signaling in the bleomycin-induced 
activation of PLD and generation of PA in the lung microvascular ECs. However, the 
regulation of PLD activation by different stimuli is complex and involves changes in 
intracellular Ca2+, protein kinase C (PKC), heterotrimeric G proteins, small molecular 
weight G proteins, and protein tyrosine kinases/protein tyrosine phosphatases (Parinandi 
et al., 2001; Varadharaj et al., 2006). The precise signaling pathway responsible for 
mediating the oxidant-induced and thiol-regulated activation of PLD caused by 
bleomycin in BLMVECs needs to be established.  
Bleomycin is an oxidant drug and has been commonly used to induce pulmonary 
fibrosis in animal models (Moeller et al., 2008; Moore and Hogaboam, 2008). Bleomycin 
is well known for its action of inducing oxidative stress and redox alteration both in vivo 
and in vitro (Kinnula and Myllarniemi, 2008; Iyer et al., 2009). Oxidation of extracellular 
cysteine and alteration of redox state in lung, induction of apoptosis and senescence in 
lung cells, and disruption of iron homeostasis due to bleomycin exposure have been 
noticed in relation to the bleomycin-induced pulmonary fibrosis (Iyer et al., 2009; Kasper 
and Barth, 2009; Mungunsukh et al., 2010; Ghio, 2009). Formation and role of lipid-
derived free radicals have been observed in bleomycin-induced lung injury indicating the 
role of lipid peroxidation in the pulmonary toxicity of bleomycin (Sato et al., 2008). Free 
 25 
radical quenchers and lipid peroxidation chain-breaking antioxidants such as α-
tocopherol has also been reported to protect against the bleomycin-induced lung injury 
suggesting the role of lipid peroxidation and lipid radicals in the pulmonary toxicity of 
the drug (Suntres and Shek, 1997).  Resveratrol, a phytochemical and antioxidant, has 
been shown to alleviate the bleomycin-induced lung injury in rats in vivo (Sener et al., 
2007). The thiol protectant, N-acetylcysteine, and the iron chelator, deferoxamine, have 
been observed to attenuate the bleomycin-induced oxidative stress and lung injury 
(Teixeira et al., 2008). Thus, these reports support our current findings that bleomycin 
induces oxidative stress, alteres thiol-redox status, activates PLD, and causes cytotoxicity 
in a redox-dependent pathway in BLMVECs and further provides evidence in favor of 
the protection of the bleomycin-induced adverse effects in the cells offered by 
antioxidants, thiol protectants, and iron chelators. 
One of the key findings of the current study was the role of PLD-generated PA in 
the cytotoxicity of bleomycin in BLMVECs. This was further confirmed by the use of the 
novel PLD-specific inhibitor FIPI (Su et al., 2009), which not only completely inhibited 
the bleomycin-induced activation of PLD but also attenuated the cytotoxicity of 
bleomycin in the lung microvascular ECs. This observation further established a link 
between the upstream activation of PLD and downstream cytotoxicity exerted by 
bleomycin in BLMVECs, thus offering evidence in favor of the role of the PLD-
generated bioactive lipid mediator PA therein. As the PLD-generated PA can further 
undergo enzymatic conversion into DAG and/or LPA, it was not clear whether the 
cytotoxicity-inducing bioactive lipid generated by PLD through bleomycin action was PA 
or DAG or LPA or combination of those. PLD-generated PA has been identified as the 
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precursor of LPA formation through the actions of PLA1/PLA2 (Aoki, 2004; Aoki et al., 
2008). LPA receptors, members of the G protein-coupled receptors, have been shown to 
be involved in several physiological and pathophysiological states (Aoki et al., 2008; 
Hama and Aoki, 2010). LPA receptors 1 and 2 have been identified to play roles in 
regulation of vascular injury (Panchatcharam et al., 2008). The role of LPA receptor 1 
linking pulmonary fibrosis to lung injury towards causing fibroblast recruitment and 
vascular leak in the bleomycin model of pulmonary fibrosis mouse model has been 
unequivocally elucidated (Tager et al., 2008). Nevertheless, the sources of LPA in these 
studies have not been identified, at least in the bleomycin pulmonary fibrosis model. On 
the other hand, the current study indicated PLD as a possible source of PA that could be 
very well converted into LPA, another potent bioactive lipid mediator, which could be 
responsible for the observed bleomycin-induced vascular EC damage. Also, it should be 
emphasized that PLD-derived PA could have also exerted its cellular effects through PA-
dependent or DAG-mediated signaling cascades.  
Overall, the current study offered a novel signaling pathway of bleomycin-
induced lung microvascular EC damage, involving the oxidative stress-mediated and 
thiol redox-regulated PLD activation and generation of the bioactive lipid mediator PA. 
Furthermore, the findings of the current study also identified PLD as a possible target for 
the therapeutic intervention of IPF. 
 
 
 
 
 27 
References 
 
1. Aoki J, Inoue A, and Okudaira S. Two pathways for lysophosphatidic acid 
production. Biochim Biophys Acta. 1781(9): 513-8, 2008. 
2. Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol. 
15(5):477-89, 2004. 
3. Behr J, and Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 
31(6):1357-67, 2008. 
4. Brindley DN and Waggoner DW. Phosphatidate phosphohydrolase and signal 
transduction. Chem Phys Lipids 80 (1-2): 45-57, 1996. 
5. Calabrese F, Giacometti C, Rea F, Loy M, and Valente M. Idiopathic interstitial 
pneumonias: Primum movens: epithelial, endothelial or whatever. Sarcoidosis Vasc 
Diffuse Lung Dis. 1:S15-23, 2005. 
6. Chopra P, Kanoje V, Semwal A, and Ray A. Therapeutic potential of inhaled p38 
mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. 
Expert Opin Investig Drugs. 17(10):1411-25, 2008. 
7. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, 
Morris AJ, and Frohman MA. Phospholipase D2, distinct phospholipase D isoform 
with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 
7 (30: 191-201, 1997. 
8. Cordier JF. Pulmonary hypertension in chronic pulmonary respiratory and cardiac 
diseases. Rev Prat. 58(18): 2019-23, 2008. 
 28 
9. Cummings R, Parinandi N, Wang L, Usatyuk P, and Natarajan V. Phospholipase 
D/phosphatidic acid signal transduction: role and physiological significance in lung. 
Mol Cell Biochem. 234-235(1-2):99-109, 2002. 
10. Devecha N and Irvine RF. Phospholipid signaling. Cell 80 (2): 269-278, 1995. 
11. Exton JH. New developments in phospholipase D. J Biol Chem 272 (25): 15579-
15582, 1997. 
12. Exton JH. Regulation of phospholipase D. Biochim Biophys Acta 1439 (2): 121-133, 
1999. 
13. Garneau-Tsodikova S, and Thannickal VJ. Protein kinase inhibitors in the treatment 
of pulmonary fibrosis. Curr Med Chem. 15(25):2632-40, 2008. 
14. Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys 
Acta.1790(7):731-9, 2009. 
15. Gosens R, Mutawe M, Martin S, Basu S, Boss ST, Tran T, and Halayko AJ. Caveolae 
and caveolins in the respiratory system. Curr Mol Med. 8(8):741-53, 2008. 
16. Hagele TJ, Mazerik JN, Gregory A, Kaufman B, Magalang U, Kuppusamy ML, 
Marsh CB, Kuppusamy P, and Parinandi NL. Mercury activates vascular endothelial 
cell phospholipase D through thiols and oxidative stress. Int J Toxicol. 26(1):57-69, 
2007. 
17. Hama K, and Aoki J. LPA(3), a unique G protein-coupled receptor for 
lysophosphatidic acid. Prog Lipid Res.Epub ahead of print, 2010. 
18. Hammond SM, Altshuller YM, Sung TC, Rudge SA, Rose K, Engebrecht J, Morris 
AJ, and Frohman MA. Human ADP-ribosylation factor-activated 
 29 
phosphatidylcholine-specific phospholipase D defines a new and highly conserved 
gene family. J Biol Chem 270 (50): 29640-29643, 1995. 
19. Houle MG and Bourgoin S. Regulation of phospholipase D by phosphorylation 
dependent mechanisms. Biochim Biophys Acta 1439 (2): 135-149, 1999. 
20. Iyer SS, Ramirez AM, Ritzenthaler JD, Torres-Gonzalez E, Roser-Page S, Mora AL, 
Brigham KL, Jones DP, Roman J, and Rojas M. Oxidation of extracellular 
cysteine/cystine redox state in bleomycin-induced lung fibrosis. Am J Physiol Lung 
Cell Mol Physiol. 296(1):L37-45, 2009. 
21. Kasper M, and Barth K. Bleomycin and its role in inducing apoptosis and senescence 
in lung cells-modulating effects of caveolin-1. Curr Cancer Drug Targets. 9(3):341-
53, 2009. 
22. Kinnula VL, Fattman CL, Tan RJ, and Oury TD. Oxidative stress in pulmonary 
fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. 
172(4):417-22, 2005. 
23. Kiss Z and Anderson WH. Hydrogen peroxide regulates phospholipase D-mediated 
hydrolysis of phosphatidylethanolamine and phosphatidylcholine by different 
mechanisms in NIH 3T3 fibroblasts. Arch Biochem Biophys 311 (2): 430-436, 1994. 
24. Liscovitch M and Chalifa-Caspi V. Enzymology of mammalian phospholipases D: in 
vitro studies. Chem Phys Lipids 80 (1-2): 37-44, 1996. 
25. Lopez I, Arnold RS, and Lambeth JD. Cloning and initial characterization of a human 
phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem 
273 (21): 12846-12852, 1998. 
 30 
26. Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P, Rothrauff S, and Ross P 
Jr. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. 
Am J Clin Pathol. 119(4):556-67, 2003. 
27. Mazerik JN, Hagele T, Sherwani S, Ciapala V, Butler S, Kuppusamy ML, Hunter M, 
Kuppusamy P, Marsh CB, and Parinandi NL. Phospholipase A2 activation regulates 
cytotoxicity of methylmercury in vascular endothelial cells. Int J Toxicol. 26(6):553-
69, 2007. 
28. Min DS, Kim EG, and Exton JH. Involvement of tyrosine phosphorylation and 
protein kinase C in the activation of phospholipase D by H2O2 in Swiss 3T3 
fibroblasts. J Biol Chem 273 (45): 29986-29994, 1998. 
29. Moeller A, Ask K, Warhurton D, Gauldie J, and Kolb M. The bleomycin animal 
model: a useful tool to investigate treatment option for idiopathic pulmonary fibrosis? 
Int J Biochem Cell Biol. 40(3):362-82, 2008. 
30. Moore BB, and Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol 
Lung Cell Mol Physiol. 294(2):L152-60, 2008. 
31. Mungunsukh O, Griffin AJ, Lee YH, and Day RM. Bleomycin induces the extrinsic 
apoptotic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol 
Physiol. Epub ahead of print, 2010. 
32. Natarajan V and Garcia JG. Agonist-induced activation of phospholipase D in bovine 
pulmonary artery endothelial cells: regulation by protein kinase C and calcium. J Lab 
Clin Med 121 (2): 337-347, 1993. 
 31 
33. Natarajan V, Scribner WM, Al-Hassani M, and Vepa S. Reactive oxygen species 
signaling through regulation of protein tyrosine phosphorylation in endothelial cells. 
Environ Health Perspect 106 (5): 1205-1212, 1998. 
34. Natarajan V, Scribner WM, and Taher MM. 4-Hydroxynonenal, a metabolite of lipid 
peroxidation, activates phospholipase D in vascular endothelial cells. Free Radic Biol 
Med 15 (4): 365-375, 1993. 
35. Natarajan V, Scribner WM, and Vepa S. Regulation of phospholipase D by tyrosine 
kinases. Chem Phys Lipids 80 (1-2): 103-116, 1996. 
36. Natarajan V, Taher MM, Roehm B, Parinandi NL, Schmid HH, Kiss Z, and Garcia 
JG. Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty 
acid hydroperoxide. J Biol Chem 268 (2): 930-937, 1993. 
37. Natarajan V, Vepa S, Shamlal R, Al-Hassani M, Ramasarma T, Ravishankar HN, and 
Scribner WM. Tyrosine kinases and calcium dependent activation of endothelial cell 
phospholipase D by diperoxovanadate. Mol Cell Biochem 183 (1-2): 113-124, 1998. 
38. Natarajan V, Vepa S, Verma RS, and Scribner WM. Role of protein tyrosine 
phosphorylation in H2O2-induced activation of endothelial cell phospholipase D. Am 
J Physiol 271 (3 Pt 1): L400-408, 1996. 
39. Natarajan V. Oxidants and signal transduction in vascular endothelium. J Lab Clin 
Med 125 (1): 26-37, 1995. 
40. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, Dong A, Lynch 
K, Chun J, Morris AJ, and Smyth SS. Lysophosphatidic acid receptors 1 and 2 play 
roles in regulation of vascular injury responses but not blood pressure. Circ. Res 
103(6):662-70, 2008. 
 32 
41. Parinandi NL, Roy S, Shi S, Cummings RJ, Morris AJ, Garcia JG, and Natarajan V. 
Role of Src kinase in diperoxovanadate-mediated activation of phospholipase D in 
endothelial cells. Arch Biochem Biophys. 396(2):231-43, 2001. 
42. Parinandi NL, Scribner WM, Vepa S, Shi S, and Natarajan V. Phospholipase D 
activation in endothelial cells is redox sensitive. Antioxid Redox Signal 1 (2): 193-
210, 1999. 
43. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, and McGoon MD. Pulmonary 
hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 82(3):342-50, 
2007. 
44. Sato K, Tashiro Y, Chibana S, Yamashita A, Karakawa T, and Kohrogi H. Role of 
lipid-derived free radical in bleomycin-induced lung injury in mice: availability for 
ESR spin trap method with organic phase extraction. Biol Pharm Bull. 31(10):1855-9, 
2008.  
45. Sener G, Topalogu N, Sehirli AO, Ercan F, and Gedik N. Resveratrol alleviates 
bleomycin-induced lung injury in rats. Pulm Pharmacol Ther. 20(6):642-9, 2007. 
46. Singer WD, Brown HA, Jiang X, and Sternweis PC. Regulation of phospholipase D 
by protein kinase C is synergistic with ADP-ribosylation factor and independent of 
protein kinase activity. J Biol Chem 271 (8): 4504-4510, 1996. 
47. Steinhour E, Sherwani SI, Mazerik JN, Ciapala V, O’Connor Butler E, Cruff JP, 
Magalang U, Parthasarathy S, Sen CK, Marsh CB, Kuppusamy P, and Parinandi NL. 
Redox-active antioxidant modulation of lipid signaling in vascular endothelial cells: 
vitamin C induces activation of phospholipase D through phospholipase A2, 
lipoxygenase, and cyclooxygenase. Mol Cell Biochem. 315(1-2):97-112, 2008. 
 33 
48. Su w, Chen Q, and Frohman MA. Targeting phospholipase D with small-molecule 
inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol. 
5(9):1477-86, 2009. 
49. Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, and 
Frohman MA. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D 
pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol 
Pharmacol. 75(3):437-46, 2009. 
50. Suntres ZE, and Shek PN. Protective effect of liposomal alpha-tocopherol against 
bleomycin-induced lung injury. Biomed Environ Sci. 10(1):47-59, 1997. 
51. Tager AM, LaCamera P, Shea SB, Campanella GS, Selman M, Zhao Z, Polosukhin 
V, Wain J, Karimi-Shah BA, Kim ND, Hart WK, Pardo A, Blackwell TS, Xu Y, 
Chun J, and Luster AD. The lysophosphatidic acid receptor LPA1 links pulmonary 
fibrosis to leak injury by mediating fibroblast recruitment and vascular leak. Nat. Med 
14(1): 45-54, 2008. 
52. Tappia PS, Dent MR, and Dhalla NS. Oxidative stress and redox regulation of 
phospholipase D in myocardial disease. Free Radic Biol Med. 41(3):349-61, 2006. 
53. Taskar V, and Coultas D. Exposures and idiopathic lung disease. Semin Respir Crit 
Care Med. 29(6):670-9, 2008. 
54. Teixeira KC, Soares FS, Rocha LG, Silveira PC, Silva La, Valenca SS, Dal Pizzol F, 
Streck EL, and Pinho RA. Pulm Pharmacol Ther. 21(2):309-16, 2008. 
55. Varadharaj S, Steinhour E, Hunter MG, Watkins T, Baran CP, Magalang U, 
Kuppusamy P, Zweier JL, Marsh CB, Natarajan V, and Parinandi NL. Vitamin C-
 34 
induced activation of phospholipase D in lung microvascular endothelial cells: 
regulation by MAP kinases. Cell Signal. 18(9):1396-407, 2006. 
56. Vuokko L. Kunnula and Marjukka Myllarniemi. Oxidant-Antioxidant Imbalance as a 
Potential Contributor to the Progession of Human Pulmonary Fibrosis. Antiox Redox 
Signal. 10(4):727-38, 2008. 
57. Wilson MS, and Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and 
regulation. Mucosal Immunol. 2(2):103-21, 2009. 
58. Zisman DA, Keane MP, Belperio JA, Strieter RM, and Lynch JP 3rd.  Pulmonary 
Fibrosis. Methods Mol Med. 117:3-44, 2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
Figure Legends 
 
Hypothesis: It is hypothesized that the lung fibrosis inducer, bleomycin, will cause the 
formation of ROS, thiol-redox alterations and PLD activation to produce bioactive lipid 
signal mediator PA.  PA will then cause further endothelial damage and barrier 
dysfunction. 
 
Figure 1: Bleomycin induces PLD activation in a dose- and time-dependant fashion in 
ECs. 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium for 12 h. Following [32P]orthophosphate labeling, cells were 
treated with different concentrations (0-100 µU) of bleomcyin (A), or for different time 
periods (4-24 h; B) in MEM containing 0.05% 1-butanol. At the end of incubation period, 
[32P]PBt formed was determined as described under Materials and Methods. Data 
represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells not treated with bleomyicn. 
 
Figure 2: Thiol-protectants attenuate bleomycin-induced PLD activation in ECs. 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were 
pretreated for 2 h with MEM or MEM containing NAC (0.5, 1, and 5 mM; A) or DTT 
(0.5, 1, and 5 mM; B) and then subjected to co-treatment with vehicle or bleomycin (5 
µU) for 12 h in presence of 0.05% (v/v) 1-Butanol.  At the end of incubation period, 
[32P]PBt formed was determined as described under Materials and Methods. Data 
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represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone. ** Significantly 
different at P<0.05 as compared to cells treated with bleomycin alone.  
Figure 3: Heavy metal chelators attenuate bleomycin-induced PLD activation in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were 
pretreated for 2 h with MEM or MEM containing EDTA (2 mM; A) or Desferal (2 mM; 
B) or DMSA (0.5, 1, 5 mM; C) and then subjected to co-treatment with vehicle or 
bleomycin (5 µU) for 12 h in presence of 0.05% (v/v) 1-Butanol.  At the end of 
incubation period, [32P]PBt formed was determined as described under Materials and 
Methods. Data represent mean ± S.D. calculated from three independent experiments. 
*Significantly different at P<0.05 as compared to cells treated with vehicle alone. ** 
Significantly different at P<0.05 as compared to cells treated with bleomycin alone.  
 
Figure 4: Antioxidants attenuate bleomycin-induced PLD activation in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were 
pretreated for 2 h with MEM or MEM containing PDTC (0.5, 1, 5 mM; A) or Propyl 
Gallate (500 µM; B) or Vitamin C (500 µM; C) or MnTBAP (20 µM; D)  and then 
subjected to co-treatment with vehicle or bleomycin (5 µU) for 12 h in presence of 0.05% 
(v/v) 1-Butanol.  At the end of incubation period, [32P]PBt formed was determined as 
described under Materials and Methods. Data represent mean ± S.D. calculated from 
three independent experiments. *Significantly different at P<0.05 as compared to cells 
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treated with vehicle alone. ** Significantly different at P<0.05 as compared to cells 
treated with bleomycin alone.  
 
Figure 5: Lipid peroxidation inhibitors attenuate bleomycin-induced PLD activation in  
 
ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were 
pretreated for 2 h with MEM or MEM containing NDGA (10, 20, 50 µM; A) or Trolox 
(100, 200, 500 µM; B) and then subjected to co-treatment with vehicle or bleomycin (5 
µU) for 12 h in presence of 0.05% (v/v) 1-Butanol.  At the end of incubation period, 
[32P]PBt formed was determined as described under Materials and Methods. Data 
represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone. ** Significantly 
different at P<0.05 as compared to cells treated with bleomycin alone.  
 
Figure 6: Bleomycin induces ROS generation in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were preloaded with 10 µM DCFDA for 30 min in 
complete MEM.  Following the DCFDA loading, cells were subjected to treatment with 
vehicle or bleomycin (0-100 µU) for 1 h (A) and 0.5 h (B).  At the end of incubation 
period, the DCFDA fluorescence (as an index of ROS formation) was determined as 
described under Materials and Methods. Each micrograph is a representative picture 
obtained from three independent experiments conducted under identical conditions.  Data 
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represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone.  
 
Figure 7: Bleomycin causes GSH depletion in ECs. 
 
BLMVECs (1 x 105 cells/96 well plates) were subjected to treatment with vehicle or 
bleomycin (0-100 µU) for 12 h.  At the end of incubation period, the intracellular soluble 
thiol concentrations were determined as described under Materials and Methods. Data 
represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone.  
 
Figure 8: Bleomycin induces lipid peroxidation in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were subjected to treatment with vehicle or 
bleomycin (0-100 µU) for 12 h.  At the end of incubation period, the cells were fixed, 
stained for 4HNE formation, and visualized using confocal microscopy as described 
under Materials and Methods. Each micrograph is a representative picture obtained from 
three independent experiments conducted under identical conditions.   
 
Figure 9: PLD inhibitor, FIPI, protects against bleomycin-induced PLD activation in 
ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were labeled with [32P]orthophosphate  in DMEM 
phosphate-free medium along with pretreatment of MEM or MEM containing FIPI (250, 
500, 1000 nM) for 12 h.  Following the [32P]orthophosphate labeling and FIPI 
pretreatment, cells were subjected to co-treatment with vehicle or bleomycin (5 µU) for 
12 h in presence of 0.05% (v/v) 1-Butanol.  At the end of incubation period, [32P]PBt 
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formed was determined as described under Materials and Methods. Data represent mean 
± S.D. calculated from three independent experiments. *Significantly different at P<0.05 
as compared to cells treated with vehicle alone. ** Significantly different at P<0.05 as 
compared to cells treated with bleomycin alone.  
 
Figure 10: Bleomycin induces cytotoxicity and morphological alterations in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were subjected to treatment with vehicle or 
bleomycin (0-100 µU) for 4-24 h.  At the end of incubation period, the morphological 
pictures (as an index of cytotoxicity) were taken as described under Materials and 
Methods. Each micrograph is a representative picture obtained from three independent 
experiments conducted under identical conditions.   
 
Figure 11: PLD inhibitor protects against bleomycin-induced morphological alterations 
in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were pretreated with complete MEM or complete 
MEM containing FIPI (1 µM) for 12 h and then subjected to co-treatment with vehicle or 
bleomycin (0-100 µU) for 4-24 h.  At the end of incubation period, the morphological 
pictures (as an index of cytotoxicity) were taken as described under Materials and 
Methods. Each micrograph is a representative picture obtained from three independent 
experiments conducted under identical conditions.   
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Figure 12: Bleomycin induces cytotoxicity in ECs. 
  
BLMVECs (5 x 105 cells/35-mm dish) were subjected to treatment with MEM alone or 
MEM containing bleomycin (0-100 µU) for 8 (A), 12 (B), and 24 (C) h.  At the end of 
incubation period, release of LDH into the medium (as an index of cytotoxicity) was 
determined spectrophotometrically as described under Materials and Methods. Data 
represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone.  
 
Figure 13: PLD inhibitor, FIPI, protects against bleomycin-induced cytotoxicity in ECs. 
 
BLMVECs (5 x 105 cells/35-mm dish) were pretreated with MEM alone or MEM 
containing FIPI (250, 500, 1000 nM) for 12 h.  Following the pretreatment, cells were 
subjected to co-treatment with vehicle or bleomycin (5 µU) for 12 h.  At the end of 
incubation period, release of LDH into the medium (as an index of cytotoxicity) was 
determined spectrophotometrically as described under Materials and Methods. Data 
represent mean ± S.D. calculated from three independent experiments. *Significantly 
different at P<0.05 as compared to cells treated with vehicle alone. ** Significantly 
different at P<0.05 as compared to cells treated with bleomycin alone.  
 
Schema 1: Proposed mechanism 
 
Schematic representation of bleomycin-induced PLD activation and generation of lipid 
signal mediator, PA, and the subsequent lung endothelium damage. 
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